First study on the peptidergic innervation of the brain superior sagittal sinus in humans. by Sampaolo, S et al.
Contents lists available at ScienceDirect
Neuropeptides
journal homepage: www.elsevier.com/locate/npep
First study on the peptidergic innervation of the brain superior sagittal sinus
in humans
Simone Sampaoloa, Giovanna Liguorib, Alfredo Vittoriab, Filomena Napolitanoa,c,
Luca Lombardia, Javier Figolsd, Mariarosa Anna Beatrice Melonea, Teresa Espositoc,e,1,
Giuseppe Di Iorioa,⁎,1
a Department of Medicine, Surgery, Neurology, Metabolic and Aging Science and Interuniversity Center for Research in Neurosciences, Second University of Naples, Italy
b Department of Veterinary Medicine and Animal Productions, University of Naples Federico II, Naples, Italy
c Institute of Genetics and Biophysics “Adriano Buzzati-Traverso”, National Research Council, Naples, Italy
d Department of Pathology, Hospital Valdecilla, University of Cantabria Medical School, Santander, Spain
e URT-IGB IRCCS Neuromed, Pozzilli, Isernia, Italy
A R T I C L E I N F O
Keywords:
Human brain
Superior sagittal sinus innervation
Immunohistochemistry
Double-labeling immunoﬂuorescence
Western blotting analysis
Neurotransmitter co-localization
A B S T R A C T
The superior sagittal sinus (SSS) of the mammalian brain is a pain-sensitive intracranial vessel thought to play a
role in the pathogenesis of migraine headaches. Here, we aimed to investigate the presence and the potential co-
localization of some neurotransmitters in the human SSS. Immunohistochemical and double-labeling immuno-
ﬂuorescence analyses were applied to paraformaldehyde-ﬁxed, paraﬃn-embedded, coronal sections of the SSS.
Protein extraction and Western blotting technique were performed on the same material to conﬁrm the
morphological data. Our results showed nerve ﬁbers clustered mainly in large bundles tracking parallel to the
longitudinal axis of the sinus, close in proximity to the vascular endothelium. Smaller fascicles of ﬁbers encircled
the vascular lumen in a spiral fashion, extending through the subendothelial connective tissue. Isolated nerve
ﬁbers were observed around the openings of bridging veins in the sinus or around small vessels extending into
the perisinusal dura. The neurotransmitters calcitonin gene related peptide (CGRP), substance P (SP), neuronal
nitric oxide synthase (nNOS), vasoactive intestinal polypeptide (VIP), tyrosine hydroxylase (TH), and
neuropeptide Y (NPY) were found in parietal nerve structures, distributed all along the length of the SSS.
Overall, CGRP- and TH-containing nerve ﬁbers were the most abundant. Neurotransmitters co-localized in the
same ﬁbers in the following pairs: CGRP/SP, CGRP/NOS, CGRP/VIP, and TH/NPY. Western blotting analysis
conﬁrmed the presence of such neurosubstances in the SSS wall. Overall our data provide the ﬁrst evidence of
the presence and co-localization of critical neurotransmitters in the SSS of the human brain, thus contributing to
a better understanding of the sinus functional role.
1. Introduction
The superﬁcial veins of the brain are mainly ﬁbrous in structure and
devoid of parietal valves (Kiliç and Akakin, 2008). Most of these veins
drain in a complex of endothelium lined, vessel-like excavations of the
dura mater known as dural or cerebral sinuses, which open into the
jugular veins at the base of the encephalus. Thus, this complex of
cerebral veins and sinuses collects the blood outﬂowing from the brain
and modulates its discharge. However, the regulatory mechanisms that
operate to maintain this delicate homeostasis are still poorly under-
stood (Edvinsson and Jansen, 1992; Vignes et al., 2007).
A major component of the brain sinuses is the superior sagittal sinus
(SSS) which is a canalicular excavation of the dura mater tracking
between the two cerebral hemispheres from the prerolandic to the
postrolandic cortex, just upon the attachment of the dura to the falx
cerebri. The SSS is roughly triangular-shaped, increases in size cranio-
caudally, and dichotomizes in the two transverse sinuses at the poster-
ior pole of the brain. The SSS is the initial segment of the brain sinusal
complex and collects blood from the veins of the anterior, lateral, and
dorsal portions of the cerebral surface.
The role of the SSS in the onset of pain resulting in primary
headaches, such as migraines, is currently debated. Studies have shown
that stimulation of the human SSS causes pain ascribed to the ﬁrst
division of the trigeminal nerve (Ray and Wolﬀ, 1940). More recently,
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electrical and mechanical stimulation of the sinus were shown to
enhance metabolic activity, blood ﬂow, and c-fos expression of the
trigeminal nucleus and of the C1/C2 segment of the spinal dorsal horn
in cat and monkey models (Goadsby et al., 1997; Goadsby and Hoskin,
1997; Kaube et al., 1993; Lambert et al., 1988). When cholera toxin
subunit b or wheat germ agglutinin horseradish peroxidase was applied
to the rat SSS, nerve structures in the trigeminal and C2 dorsal root
ganglia, the medullar trigeminal nucleus, and the C1/C3 segment of the
spinal dorsal horn were labeled through retrograde intra-axonal trans-
port of both molecules (Liu et al., 2004). Taken together, these ﬁndings
suggest that the SSS is a sensitive vessel capable of sending algic
sensations to the spinal trigeminal nucleus. Particularly, the SSS is
considered the more nociceptive-speciﬁc structure of the brain
(Goadsby et al., 2009).
Morphological studies of SSS innervation are a necessary comple-
ment to the functional ones, but remain largely incomplete. Many
decades ago, the ﬁbers innervating the SSS walls were shown to
originate from the ophthalmic division of the trigeminal nerve.
Particularly, the initial portion of the sinus received ﬁbers through
the anterior ethmoidal nerves, while the posterior third was innervated
by ﬁbers from the falx (McNaughton, 1966). More recently the rat SSS
was found to be encircled by dopamine β hydroxylase-containing nerve
ﬁbers which probably originated from neurons of the left and right
superior cervical ganglia, which resulted intensely stained when the
complex wheat germ agglutinin/horseradish peroxidase was applied to
the supratentorial dura (Keller et al., 1989). Further, dense network of
nerve ﬁbers containing the peptides calcitonin gene related peptide
(CGRP), substance P (SP), neuropeptide Y (NPY), and vasoactive
intestinal polypeptide (VIP), and the amine serotonin were described
around the SSS of the same animal species (Keller and Marfurt, 1991).
These studies were performed by ﬂuorescent and immunohistochemical
analyses of whole mount preparations of dural strips and provided an
elegant description of the perisinusal innervation, but were unable to
disclose the distribution of such ﬁbers within the SSS walls.
Finally, close networks of NPY- and SP-containing nerve ﬁbers were
described around the superior sagittal and transverse sinuses in the cat
(von Düring et al., 1990), and around the SSS in the guinea pig (Furness
et al., 1982), respectively. In particular, the ﬁrst study showed that all
branches of the NPY-containing network comprised small or large
bundles of unmyelinated ﬁbers, while the second described perivascu-
lar SP-containing innervation of the total animal body.
In this study we investigated the presence of a neurotransmitter pool
in the SSS sinusal wall of the human brain using immunohistochemical
and double-labeling immunoﬂuorescent techniques. We also investi-
gated the co-localization of the tested molecules in the same nerve
ﬁbers of the SSS. Western blotting analysis was used as well to validate
the presence of the neuropeptides. Our results may provide further
insight to better understand the role of these neurotransmitters in the
pathogenesis of migraine headaches.
2. Material and methods
2.1. Samples
The tissues used in this study were collected from 20 human
cadavers of both gender humans who had died from causes unrelated
to cerebral pathologies and whose brains were found to be free of
lesions during necroscopic analysis. All samples were collected at the
Hospital Universitario Marqués de Valdecilla, Santander (Spain), care-
fully following the procedures described by the Declaration of Helsinki
for experimental use of biological material of human provenience.
2.2. Tissue collection, ﬁxation, and processing
After craniotomy and dural laminectomy, the SSS of each subject
was carefully collected and transversely cut with a razor blade in
0.5–0.7 cm-thick sections, which were immersed in a 4% paraformal-
dehyde solution in 0.1 M phosphate buﬀered saline (PBS, pH 7.4) for
18–24 h. Subsequently, the material was washed overnight in cold
buﬀer, dehydrated in a series solutions with increasing ethanol content,
kept for 48 h in methylbenzoate, and ﬁnally, embedded in paraﬃn. For
the embedding process, samples were oriented to obtain transverse
sections of the sinus (7 μm in thickness), which were cut by a Minot
type microtome. Sequences of seriated sections were cut and mounted
on numbered slides to follow the entire length of long parietal nerve
structures. Sections were mounted on poly-L-lysine-coated slides and
stained using either the avidin-biotin immunohistochemical technique
or the double-labeling immunoﬂuorescence method described by
Wessendorf and Elde (1985). Before staining, all sections were sub-
jected to an antigen unmasking procedure, performed by immersion in
a citrate buﬀer (pH 6.0) and double permanence (5 min each) in a
microwave oven at 750 W as described elsewhere (Liguori et al., 2017).
Other sections were submitted to a protein extraction method utilizing
a speciﬁc kit in order to perform a Western blotting (WB) analysis of the
polypeptide residue.
2.3. Immunohistochemistry
The immunohistochemical procedure was performed as previously
described (De Luca et al., 2014; Liguori et al., 2014). After the
dewaxing and unmasking steps, the sections were washed and quickly
submerged in 3% hydrogen peroxide solution for 30 min at room
temperature to inhibit endogenous peroxydases. Afterward, they were
washed three times in PBS and blocked with normal serum for 30 min.
Sections were incubated with primary antibodies overnight at 6 °C. The
following day, they were incubated with the secondary antibody for
30 min at room temperature. The site of the immunological reaction
was visualized with an avidin-biotin complex applied for 30 min at
room temperature, followed by staining with 3.3-diaminobenzidine.
Finally, sections were dehydrated, clariﬁed, and mounted for visualiza-
tion.
2.4. Double-labeling immunoﬂuorescence
The unmasking procedure was performed as described above.
Normal sera from the two donor species of the secondary antibodies
were applied in a unique mixture. The two primary antibodies were
raised in diﬀerent donor species and applied simultaneously on each
section. Additionally, the two secondary antibodies were applied
simultaneously and were conjugated to the brief wavelength ﬂuoro-
chrome ﬂuorescein isothiocyanate (FITC) or to the long wavelength
ﬂuorochrome tetramethylrhodamine isothiocyanate (TRITC), respec-
tively. Primary and secondary antibodies were incubated on sections
overnight at 6 °C and for 1 h at room temperature, respectively. All
sections were kept in a dark and humid environment to prevent
photobleaching and evaporation. Stained sections were mounted with
glycerol/PBS (1:2) and visualized immediately. FITC was visualized
with a 450–490 nm bandpass excitation- and a 525/20 nm bandpass
barrier-ﬁlter, and TRITC was visualized with a 546/19 nm bandpass
excitation- and a 580 nm longpass barrier-ﬁlter. These ﬁlter sets
eliminate any red emission during blue excitation and green-yellow
emission during green excitation.
For the immunohistochemistry (IHC), all washes were done with
PBS, while those for the immunoﬂuorescence method were done with
PBS containing 0.3% Triton X-100. Normal sera were used prior to the
primary antibody step as a blocking agent. These sera were obtained by
the donor species of the secondary antibody. Both normal and
ﬂuorescent light preparations were observed using a Nikon Eclipse E
600 microscope equipped with a reﬂection system for ﬂuorescence and
photographed by a Coolpix 8400 Digital Camera. A 10× ocular lens
was used in combination with the following objective lenses: 20× [dry;
numerical aperture (NA) 0.50], 40× (dry; NA 0.75), 60× (dry; NA
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0.85), and 100× (oil immersion; NA 1.30). Some sections were stained
by EE to obtain general view of the vessel walls and of the structures
contained around and within them.
Negative controls for primary antibody speciﬁcity were obtained by
pre-absorbing the primary antibody with an excess (100 μg/ml) of the
relative antigen for use at the primary antibody step. The control for
secondary antibody speciﬁcity was normal serum. All controls pro-
duced negative results. To avoid cross-reaction between tissue antigens
and/or immunoﬂuorescence reagents, the following tests were em-
ployed as controls: 1) aﬃnity of the primary antibodies to heterologous
antigens; 2) aﬃnity of the secondary antibodies to the heterologous
primary antibodies; 3) aﬃnity of the primary antibodies to each other;
4) aﬃnity of the secondary antibodies to each other; 5) aﬃnity of the
primary antibodies for the heterologous secondary antibodies; 6)
emission of green and red light by one of the two ﬂuorochromes. The
protocols for these controls are described in detail by Wessendorf and
Elde (1985).
2.5. Image processing
The light and ﬂuorescent images were photographed and analyzed
on a personal computer. Some of them were adjusted for contrast,
brightness, and uniformity of illumination. Using Adobe Photoshop
CS5, images for each ﬁlter were superimposed, and then the scale bars
were applied before preparing the ﬁnal ﬁgure layout.
2.6. Protein extraction and Western blotting analysis
The proteins contained in sections from paraﬃn-embedded SSS
samples were extracted using a Qproteome Formalin Fixed Paraﬃn-
embedded (FFPE) Tissue Kit (Qiagen, Hilden, Germany) which provides
optimized conditions for non-degraded total protein extraction from
FFPE tissues (Becker et al., 2007). Brieﬂy, 12 tissue sections (15 μm
thick) were deparaﬃnized in xylene, rehydrated in graded alcohol
series and mixed with 100 μl of extraction buﬀer EXB supplemented
with β-mercaptoethanol and 1× Protease and Phosphatase Inhibitor
Cocktail (Sigma). The samples were cooled on ice for 5 min, and were
successively incubated at 100 °C for 20 min and at 80 °C for 2 h on a
heating block, under continuous shaking. Total proteins were recovered
after centrifugation at 1400 ×g at 4 °C for 15 min and their concentra-
tion was determined with the Bradford protein assay using Bovine
Serum Albumin (BSA) as standard.
For WB analysis 1× Laemmli buﬀer and β-mercaptoethanol were
added to 38 μg and 22 μg of proteins obtained from two subjects
deﬁned as subject 1 (S1) and 2 (S2), respectively. The proteins were
denatured by heating at 95 °C for 5 min and separated on 12% SDS-
PAGE Polyacrylamide gel in Running Buﬀer (1× Tris-Glycine, 1%
SDS), for 1–3 h at 100 V. Then the proteins were transferred onto 0.45-
m-pore size Immobilon-P membranes (Millipore, Bedford, MA) by using
the “transfer sandwich” procedure performed in transfer buﬀer (1×
Tris-Glycine, 20% Methanol), at 4 °C for 1 h at 100 V. Membranes were
incubated with the blocking buﬀer (5% nonfat dried milk powder in
1× TBS, 0.05% Tween 20) for 1 h under continuous shaking at room
temperature. Finally, the proteins were incubated in blocking buﬀer
diluted primary antibodies over night at 4 °C and then in blocking
buﬀer diluted secondary antibodies for 1 h at room temperature. The
proteins were visualized using Advansta ECL and X-ray analysis. This
latter was performed using a CAWOMAT 2000 IR machine. All
neurosubstances investigated by IHC and IF have been searched by
WB analysis.
2.7. Antibodies
The primary antibodies used in this study were monoclonal or
polyclonal peptides whose characteristics were carefully checked for
speciﬁcity before acquiring them commercially. They are listed below.
Protein gene product (PGP) 9.5 was used as a marker for nerve
structures. PGP 9.5 was detected with the same antibody used here at
the expected size of 27 kDa in rat brain cell lysates examined by WB
analysis. The antibody also detected PGP 9.5 in neuronal cell bodies
and axons in the CNS and periphery, nerve ﬁbers in peripheral tissues,
neuroendocrine cells in the pituitary gland, thyroid gland, and pan-
creas, and tumors of the diﬀuse neuroendocrine system. The nerve
structures stained here were morphologically similar to those described
by others using a diﬀerent anti-PGP 9.5 antibody in other organs (Xue
et al., 2000).
The guinea pig anti-α- CGRP antibody demonstrated high speciﬁcity
for the α and β variants of human CGRP [100% binding speciﬁcity for
human α-CGRP, α-CGRP(8–37), and β-CGRP] as shown using the
radioimmunoassay (RIA) application. This antibody also exhibited
binding speciﬁcity for similar antigens (displayed as binding speciﬁcity
percentages): chicken CGRP (30%), rat α-CGRP (25%), human amylin
(8%), rat amylin (0%), human calcitonin (0%), and salmon calcitonin
(0%). A second anti-α-CGRP antibody (6006 T 4032), which was
produced by the same manufacturer, displayed similar staining patterns
and speciﬁcities as those described above (Lennerz et al., 2008).
The goat polyclonal anti-CGRP antibody detected CGRP 1 (α-CGRP)
and CGRP 2 (β-CGRP) of mouse, rat and human origin by WB, IF, and
solid phase ELISA. This antibody is also recommended for the detection
of the two molecular variants in equine, canine, bovine, porcine and
avian species.
The anti-SP antibody detected SP of rat, mouse, and human origin
by WB, immunoﬂuorescence (IF), IHC (formaldehyde ﬁxation/paraﬃn
embedding), and solid-phase ELISA techniques. SP from equine, canine,
bovine, porcine, and avian species was detected as well. The antibody
speciﬁcally stained human pancreatic Langherans islet cells by means of
indirect IHC.
The anti-neuronal nitric oxide synthase (nNOS) antibody detected
human nNOS by WB, immunoprecipitation, IHC (including paraﬃn-
embedded material), IF, and solid-phase ELISA. The antibody revealed
band at 155 kDa in lysates from in vitro cultured rhabdomyosarcoma
cells (A673) examined by WB analysis and stained human cerebellar
Purkinje cells using the immunoperoxidase technique applied to
sections from formalin-ﬁxed/paraﬃn-embedded material.
The anti-VIP antibody showed high reactivity for VIP and, to a lesser
extent, for pituitary adenylate cyclase-activating polypeptide (PACAP)
of mouse, rat, and human origin as shown in WB, IF, and solid-phase
ELISA techniques. The antibody was used for VIP detection in horse,
dog, cattle, pig, and avian tissues as well. This antibody detected a
20 kDa polypeptide in lysates from neuroblastoma cells (SK-N-SH) and
mouse brain extracts and speciﬁcally stained the cytoplasm of the same
cells when tested by indirect IF.
The enzyme tyrosine hydroxylase (TH) is considered a molecular
marker for sympathetic nerve structures. The monoclonal antibody that
we used here detected TH of mouse, rat, and human origin by WB,
immunoprecipitation, IF, and solid-phase ELISA. The antibody detected
a 60 kDa protein by WB analysis in PC-12 whole cell lysates, consistent
with the theoretical molecular weight of TH: 56 kDa.
Finally, the anti-NPY antibody speciﬁcally detected NPY of mouse,
rat, and human origin by WB, IF, and solid-phase ELISA. This antibody
also bound NPY from equine, bovine, porcine, and avian species.
All the antibodies described above have been used to perform IHC,
IF and WB analysis with the exception of those directed against CGRP of
which, the ﬁrst (second in the list) was utilized for IHC and IF, and the
second (third in the list) was used for WB. The peculiarities of all
primary antibodies are described in Table 1.
The secondary antibodies used in this work were also commercially
acquired and are immunoglobulins derived from diﬀerent animal
species conjugated to biotin, ﬂuorochromes FITC or TRITC and horse-
radish peroxidase. The antibodies used for IHC and IF are listed in
Tables 2 and 3, respectively, while those used for WB are listed in
Table 4.
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3. Results
3.1. Immunohistochemical and immunoﬂuorescent ﬁndings
Using the antibody directed against the neuronal marker PGP 9.5,
we visualized the nerve structures contained in the walls of the SSS
through a series of coronal sections. The sinusal wall can be challenging
to deﬁne in a morphological study of the cerebral sinuses because of the
lack of the wall musculature. However, data produced through the
experimental application of retrograde neuronal tracers to the dura
encircling the SSS lumen of the rat allowed Liu et al. (2004) to mark the
medullary areas of sensitive ﬁber reception that were functionally
related to the sinus. When the neuronal tracer application was enlarged
to a dura more distant from the vessel, the ﬁeld of reception was
extended. Therefore, we deﬁned the nerve structures contained within
the range of 1000 μm from the vessel endothelium as “parietal.”
The parietal nerve ﬁbers extended primarily parallel to the long-
itudinal axis of SSS and were frequently grouped in large bundles whose
components appeared as small and round structures in coronal sections
of the vessel. These bundles lacked a connective envelope and their
ﬁbers ran discretely, but in close proximity, to each other (Fig. 1a, d, f).
Small clusters of ﬁbers wrapped by a thin connective envelope were
observed rarely in parietal structures (Fig. 1b), and became more
frequent as more they were distant from the SSS lumen in the
supratentorial dura. Single ﬁbers were seen around small blood vessels
tracking along the sinusal wall (Fig. 1c). Sometimes such vessels were
supposed to be the ﬁnal portion of venules conﬂuent into the SSS
because showed large dimension and close proximity to sinusal lumen
(see beyond the Fig. 2f). Occasionally, fascicles of ﬁbers, likely
originating from a longitudinal bundle, seemed to change direction
and encircle the sinusal lumen. This pattern gave rise to a small group
of subendothelial nerve ﬁbers obliquely or longitudinally cut in coronal
sections of the vessel (Fig. 1e, g). The ﬁbers of a subendothelial fascicle
traversed at a short distance from each other, and the most superﬁcial
of them seemed to be close in contact with the endothelium.
Nerve ﬁbers containing the neurotransmitters CGRP, SP, nNOS, VIP,
TH, and NPY were observed all along the length of SSS, although their
abundance varied widely over the ﬁeld of view. For each neurotrans-
mitter, areas of high density, low density, and absence of signal were
observable. The localization of the diﬀerent ﬁber types was fairly
uniform, with some exceptions. CGRP- (Fig. 2a–c) and TH- (Fig. 3a–c)
containing nerve ﬁbers appeared to be more numerous than the other
types. The two neurotransmitters were present both in parietal (Fig. 2a,
c and Fig. 3a, c, respectively) and subendothelial (Fig. 2b and Fig. 3b,
respectively) nerve ﬁbers. The parietal ﬁbers were mainly organized in
large bundles traversing parallel to the SSS lumen. This pattern was
followed by long series of consecutive sections. Areas of the SSS walls
that completely lacked of ﬁbers containing these two neurotransmitters
were rare. SP- (Fig. 2e–g), nNOS- (Fig. 2i–k) and NPY- (Fig.3e–g)
containing nerve ﬁbers showed similar patterns, but were less abun-
dant. SP-containing ﬁbers were the least abundant of all the tested
types, and were often localized around the opening of bridging veins
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Table 2
List of secondary antibodies used for Immunohistochemistry.
Secondary
antibodies
Conjugated To Source Dilution
Goat anti-rabbit Biotin Vector Laboratories,
Burlingame, CA; BA-1000
1:200
Goat anti-guinea
pig
Biotin Vector Laboratories,
Burlingame, CA; BA-7000
1:200
Rabbit anti-goat Biotin Vector Laboratories,
Burlingame, CA; BA-5000
1:200
Goat anti-mouse Biotin Vector Laboratories,
Burlingame, CA; BA-9200
1:200
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into the SSS lumen (Fig. 2f). As with the other types, VIP-containing
nerve ﬁbers (Fig. 2m–o) were frequently seen extending longitudinally
in the sinusal wall (Fig. 2m), but were not present in the subendothelial
connective tissue. Moreover, these ﬁbers often encircled blood vessels
contained within the supratentorial dura, distant from the SSS lumen
(Fig. 2n, o). The images of the negative controls contained in Fig. 1 (h),
Fig. 2 (d), (h), (l), (p), and Fig. 3 (d), (h) were obtained as described
above.
Furthermore, we tested the co-localization of the neurotransmitters
within the nerve structures of the sinusal wall. The following pairs of
Table 3
List of secondary antibodies used for immunoﬂuorescence.
Secondary antibodies Conjugated to Source Dilution
Goat anti-rabbit FITC Jackson ImmunoResearch Laboratories, Baltimore Pike, West Grove, PA; 111-095-144 1:100
Goat anti-guinea pig TRITC Jackson ImmunoResearch Laboratories, Baltimore Pike, West Grove, PA; 106-025-003 1:100
Donkey anti-goat TRITC Jackson ImmunoResearch Laboratories, Baltimore Pike, West Grove, PA; 705-025-003 1:100
Donkey anti-mouse TRITC Jackson ImmunoResearch Laboratories, Baltimore Pike, West Grove, PA; 715-025-150 1:100
Donkey anti-guinea pig FITC Jackson ImmunoResearch Laboratories, Baltimore Pike, West Grove, PA; 706-095-148 1:100
Donkey anti-goat FITC Jackson ImmunoResearch Laboratories, Baltimore Pike, West Grove, PA; 705-095-003 1:100
Table 4
List of secondary antibodies used for Western blotting.
Secondary
antibodies
Conjugated to Source Dilution
Goat anti-mouse
IgG1
HRP Santa Cruz Biotechnology, Santa
Cruz, CA, USA; sc-2060
1:5000
Rabbit anti-goat
IgG (H + L)
HRP Bio-Rad, Laboratories, Milano,
Italy; 172-1034
1:1000
Goat anti-rabbit
IgG (H + L)
HRP Biorad Laboratories, Milano,
Italy 170-6515
1:1000
Fig. 1. PGP 9.5-immunoreactive nerve structures contained within the SSS wall. (a) Transverse section of a large nerve ﬁber bundle extending parallel to the longitudinal axis of the vessel
in the SSS wall. The nerve ﬁbers appear as punctiform structure at a low magniﬁcation. On the left, the sinus endothelium (double arrow) and lumen (asterisk) are visible. (b) Small
bundles of parietal ﬁbers (arrow) encircled by a connective envelope can be seen in proximity of the sinusal lumen. (c) Perivascular nerve ﬁbers (arrow) adjacent to a small blood vessel
(arrowhead) extending parallel to the SSS major axis and in proximity to its lumen. (d) and (f) Parietal bundles of nerve ﬁbers transversely or obliquely cut. Each bundle comprises many
ﬁbers not enveloped by a connective sheet. The ﬁbers are distinct from each other in close proximity. (e) and (g) Subendothelial fascicles of nerve ﬁbers encircle the SSS lumen (asterisks)
in a spiral fashion, appearing obliquely cut in a transverse section of the sinus. (h) negative control for anti-PGP 9.5 immunoreaction. Images were produced using avidin-biotin
immunohistochemical and double-labeling immunoﬂuorescence techniques. Scale bars: a = 100 μm; b–d = 20 μm; e–f = 40 μm; g, h = 30 μm.
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neurotransmitters were found to co-localize in parietal ﬁbers: CGRP/SP
(Fig. 4a-c), CGRP/nNOS (Fig. 4d–f), CGRP/VIP (Fig. 4g–i), and NPY/TH
(Fig. 4j–l). The co-localization between the two neurotransmitters of
each pair was always high, as shown in the merged images of Fig. 4
(right column).
3.2. Neuropeptide detection by Western blotting analysis
In order to conﬁrm the presence of the selected neuropeptides in the
SSS, WB analysis was performed on proteins extracted by paraﬃn
embedded tissues. Protein expression was conﬁrmed for all the
analyzed substances which were present in samples from both the
subjects examined. The molecular weights assessed for the single
neuropeptides are consistent with those currently attributed to the
respective molecules contained in nerve tissues of mammals. As
expected the protein band obtained for PGP 9.5, already reported as
a marker of nerve structures, is the most prominent and can be
considered as a warranty of the presence of such structures in the
samples examined. The double band obtained for CGRP are consistent
with the theoretical molecular weights of the two variants of the
substance. The results obtained for the WB analysis performed in this
study are shown in Fig. 5.
4. Discussion
4.1. CGRP/SP-containing nerve ﬁbers
Although the morphological studies have shown the presence of
CGRP- and SP-containing nerve ﬁbers in the SSS wall (Furness et al.,
1982; Keller and Marfurt, 1991), our results provide the ﬁrst evidence
of co-localization of these two neuropeptides in the same perisinusal
ﬁbers of human SSS. The origin of these ﬁbers is probably represented
by the CGRP- and SP-producing nerve cell bodies contained in the
trigeminal ganglion, which are known to project their peripheral axons
toward cerebral arteries (Hanko et al., 1986) and various orofacial
targets (Gibbins et al., 1985; Lee et al., 1985). CGRP and SP encourage
vasodilation, the ﬁrst being the most potent known vasodilating agent
(Brain et al., 1985). The CGRP/SP-containing ﬁbers innervating the SSS
walls should act as nociceptor neurons. Electrical or mechanical
stimulation of the SSS or medial meningeal artery causes pain similar
to that perceived during headache in humans and this sensation must
be referred to the ﬁrst division of the trigeminal nerve (Ray and Wolﬀ,
1940). The previously mentioned studies in cat (Goadsby et al., 1997)
and monkey (Goadsby and Hoskin, 1997) SSS models, as well as tracing
the medullary target of the sinus-sensitive nerve ﬁbers in the rat (Liu
Fig. 2. Presence of neurotransmitters in parietal nerve ﬁbers of the SSS. (a), (b), and (c) CGRP- and (e), (f), and (g) SP-containing nerve ﬁbers were observed frequently clustered in
bundles of parietal (a, c, e, and g) or subendothelial (b) structures. SP-containing nerve ﬁbers (f) were observed in proximity of the openings of bridging veins (hash) into the SSS lumen
(asterisk). (i) and (k) nNOS- and (m), (n), and (o) VIP-containing nerve ﬁbers were observed tracking longitudinally along the SSS walls. Small fascicles of nNOS-expressing ﬁbers (j) also
encircled the sinusal lumen (asterisk) below the endothelium (double arrow), while isolated (n) or clustered (o) VIP-expression ﬁbers (arrows) were observed in close contact with the
blood vessels in the perisinusal dura. (d), (h), (l) and (p) negative controls for anti-CGRP, -SP, -nNOs, -VIP immunoreactions, respectively. Images were produced using avidin-biotin
immunohistochemical and double-labeling immunoﬂuorescence techniques. Scale bars: a, c, e, f, h = 80 μm; b, d = 50 μm; g = 100 μm; i, k = 40 μm; j, l = 25 μm; m–p = 60 μm.
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et al., 2004), clearly demonstrate the nociceptive function of a portion
of sinus wall innervation. Nociceptive nerve ﬁbers of the cat SSS,
classiﬁed morpho-pharmacologically as Aδ, Aβ, or C types, respond to
electrical, mechanical, and chemical stimuli and project to the ipsilat-
eral trigeminal spinal nucleus (Davis and Dostrovsky, 1988).
The CGRP/SP-containing neurons of the SSS walls could also
function as mechano-receptors. The muscular component of the walls
of the cerebral sinuses is minimal, and blood inﬂux coming from the
bridging veins could easily cause sinus dilatation and rise of blood
pressure. Muscle sphincters encircling the vein openings in the sinus
have been thought to regulate blood inﬂux and pressure (Vignes et al.,
2007). Interestingly, Ruﬃni-like nerve terminals have been detected by
electron microscopy around the vein openings (Andres et al., 1987) and
were thought to function as stretch receptors to monitor blood pressure.
Notably, several types of stimuli excite the meningeal sensory nerve
ﬁbers including, mechanical (e.g., punctuate probing, stroking, trac-
tion), thermal (i.e. cold or warm stimuli), chemical (e.g. hypertonic
saline), algesic (caused by potassium chloride), low/high osmolarity
buﬀer solutions, and a mixture of inﬂammatory substances (bradykinin,
prostaglandin E2, serotonin, and histamine) (Messlinger et al., 2006). If
these nerves function as mechano-receptors, they may help to modulate
responses to these stresses and regulate blood inﬂux and pressure.
Some capsaicin-sensitive sensory neurons that project toward the
wall of blood vessels can drive an eﬀerent impulse (Maggi and Meli,
1988). This phenomenon is analogous to the “axon reﬂex mechanism”
of cutaneous tissue and consists of antidromic activation of collateral
branches of sensory neurons following the peripheral stimulation of
their axon. Morpho-functional studies on the trigeminal vascular
complex have highlighted that the CGRP/SP-containing neurons of
the complex are examples of capsaicin-sensitive sensory neurons (Escott
et al., 1995). Electrical stimulation of the trigeminal ganglion caused
CGRP and/or SP release from the relative sensory terminals (Goadsby
et al., 1988) and enhancement of extracerebral blood ﬂow (Goadsby
and Duckworth, 1987). Moreover, electrical (Zagami et al., 1990) or
capsaicin (Geppetti et al., 1990) stimulation of the SSS dural wall
caused CGRP release from the surrounding nerve ﬁbers. Based on these
ﬁndings, the CGRP/SP-secreting neurons of the trigeminal vascular
complex are thought to play a pivotal role in the algic phase of migraine
pathogenesis. CGRP/SP-secreting neurons may cause a diﬀuse vasodi-
latation through neurotransmitter release and drive the stimuli that
cause the pain (Edvinsson and Linde, 2010; Keller and Marfurt, 1991;
Tajti et al., 2015). The experimental dilatation of a superﬁcial vessel of
the brain (artery or vein) is a well-known source of pain, in this case
attributable to the ophthalmic division of the trigeminal nerve (Martins
et al., 1993). The intensity of pain may be a direct function of the
amount and diﬀusion of vasodilatation (i.e. vasodilator liberation)
because CGRP levels are elevated during high levels of pain, including
during the headache phase of migraines (Gallai et al., 1995), cluster
headaches (Fanciullacci et al., 1995), chronic paroxysmal hemicranias
(Goadsby and Edvinsson, 1996), and throbbing exacerbations of
chronic tension-type headaches (Ashina et al., 2000). In contrast, CGRP
levels are low during less-developed migraine (Tvedskov et al., 2005).
The hypothesis is also supported by the clinical ﬁnding that, during
nitroglycerin-induced migraine attacks, the intensity of pain decreases
in parallel with blood CGRP levels after sumatriptan administration
(Juhasz et al., 2005). In cat models, CGRP release upon SSS stimulation
is not inhibited by administration of CP122288 (Knight et al., 1999a) or
4991w93 (Knight et al., 1999b), which are structurally modiﬁed
analogues of sumatriptan and zolmitriptan respectively, ineﬀective in
migraine suﬀerers. The physiological level of CGRP grew during a
migraine attack and caused a typical algic phase in migraneurs alone
(Kaiser and Russo, 2013). These ﬁnding further support the importance
of CGRP as mediator of vasodilatation in the headache phase of
migraines. On the contrary, the administration of the speciﬁc CGRP
antagonist, BIBN 4096 BS, is a valid treatment for acute migraine
headaches (Petersen et al., 2005).
Recently, CGRP release within the trigeminal ganglion was shown
to stimulate the secretion of cytokines from gangliar satellite glial cells,
which synthesize both the subunits of the CGRP receptor, the calcitonin
receptor-like receptor (CLR), and receptor activity-modifying protein
(RAMP) 1 (Eftekhari et al., 2010). Hypothetically, these cytokines could
modulate the activity of the CGRP-containing neurons, thus suggesting
an intraganglionic crosstalk between the two cellular populations
(Vecsey et al., 2015). CGRP-containing nerve ﬁbers and CLR/RAMP 1
immunoreactivity have been found around nerve cell bodies and within
satellite glial cells of the sphenopalatine ganglion, respectively. This
ﬁnding led to the hypothesis that CGRP release in the trigeminal
vascular complex can inﬂuence not only the sensitive component of the
complex, but also its parasympathetic counterpart (Csati et al., 2012).
In trigeminal nerve ﬁbers, CGRP and SP exhibit close relationships
at subcellular level by co-localizing in the same secretory vesicles. In
spite of this, SSS stimulation did not cause SP plasma level elevation
(Zagami et al., 1990), and blockade of the neurotransmitter receptor
was ineﬀective to treat acute migraine headaches (May and Goadsby,
Fig. 3. Presence of neurotransmitters in parietal nerve ﬁbers of the SSS. (a), (b), and (c) TH- and (e), (f), and (g) NPY-containing nerve ﬁbers were similar to those described for the other
four types both in the parietal (a, c, e, and g) and subendothelial (b and f) connective tissue of the SSS. TH-containing ﬁbers were spread diﬀusely along the sinusal walls. (d) and (h)
negative controls for anti-TH and -NPY immunoreactions, respectively. In (b) and (f) the asterisks indicate the SSS lumen and the double arrows the SSS endothelium. Images were
produced using avidin-biotin immunohistochemical and double-labeling immunoﬂuorescence techniques. Scale bars: a, c, d, f = 100 μm; b = 50 μm; e, h = 80 μm; g = 40 μm.
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2001). On the other hand, SP causes plasma protein extravasation and
vasodilatation during trigemino-vascular complex activation
(Moskowitz, 1993), and SP receptor antagonists inhibited the response
of the second order sensory neurons of the trigeminal nucleus caudalis
after trigeminal ganglion electrical stimulation (May and Goadsby,
2001). Such conﬂicting results remain unexplained, and the role of the
neuropeptide in human vascular nociception is still unclear (Holthusen
et al., 1997; Tajti et al., 2015).
In this study, the neuropeptide CGRP was found to co-localize with
the enzyme NOS in nerve ﬁbers of the SSS walls. The origin of these
ﬁbers may be the trigeminal ganglion cell bodies, which contain both
CGRP and NOS (Edvinsson et al., 1998). In vitro studies showed that
NO increased the production of CGRP from trigeminal ganglion neurons
(Eberhardt et al., 2009), while a vasodilatory eﬀect of the substance
during the algic phase of migraine was doubtful (Edvinsson et al.,
1993). Nothing is known about a potential synergistic action of NO and
CGRP peripherally released by the relative nerve ﬁbers.
4.2. Parasympathetic nerve ﬁbers
The sphenopalatine and otic ganglia were shown to be the source of
the parasympathetic nerve ﬁbers that project toward the superﬁcial
vascular bed of the brain (Edvinsson et al., 2001). These ganglia contain
cell bodies that produce acetylcholine (Ach), the well-known mediator
of the parasympathetic nervous impulse, and the neurotransmitters NO,
VIP, and PACAP (Uddman et al., 1999). ACh causes vasoconstriction of
endothelium-deprived cerebral vessels in several species (Lee, 1980),
but a wide array of experimental data, also obtained at ultrastructural
level, led to the hypothesis that, in the cerebrovascular complex, Ach is
probably co-released with NO, VIP, or PACAP which act as the last link
Fig. 4. Co-localization of neurotransmitters in parietal nerve ﬁbers of the SSS wall. The ﬁrst two images in each row were taken of the same microscopic ﬁeld at a constant focal length
using FITC (yellow/green, left) and TRITC (red, center) ﬁlter columns. The third image of each line (right) is the merged image (M), showing areas of yellow-orange ﬂuorescence to
represent sites of co-localization. The observed neurotransmitters that co-localized include: (a) CGRP and (b) SP, (c) displays the merged image; (d) CGRP and (e) nNOS, (f) displays the
merged image; (g) CGRP and (h) VIP, (i) displays the merged image (j) NPY and (k) TH, (l) displays the merged image. All images are representative examples of nerve ﬁber bundles that
simultaneously contain two neurotransmitters. Areas of co-localization for each pair of neuropeptides were widely diﬀuse. Double-labeling immunoﬂuorescence method. Bars: a, b, c, g,
h, i, j, k, l = 5 μm; d, e, f = 25 μm. (For interpretation of the references to color in this ﬁgure legend, the reader is referred to the web version of this article.)
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in nerve impulse transmission. Thus, stimulation of the parasympa-
thetic nerve ﬁbers of the brain surface vessels led to diﬀerent
vasodilatation kinetics, based on the characteristics of these three
vasodilators (Jansen-Olesen et al., 1994). Alternatively, these neuro-
peptides may act as post-junctional messengers, released through the
cholinergic stimulation of a pre-junctional receptor (Lee, 2000).
The labile molecule NO, produced from NOS, gained importance in
the headache pathogenesis when research showed that administration
of glyceryl nitrate, an NO donor molecule, caused a migraine attack in
human healthy volunteers and migraine suﬀerers (Olesen et al., 1995).
However, the explanation of this ﬁnding remains obscure. NO can be
liberated, in the trigemino-vascular complex as elsewhere in the body,
not only by nitrergic nerve ﬁbers but also from the vascular endothe-
lium and from tissue mast cells. NO causes decrease of intracellular Ca+
+ levels and vasodilatation (Olesen et al., 1995). Nerve ﬁbers contain-
ing nNOS are widespread and diﬀuse in the cerebral vessel network
(Bredt et al., 1990), and nNOS was found to co-localize with VIP and
acetylcholinesterase (AChE) in perivascular cerebral nerve ﬁbers of rat
and cattle brains. Thus, nNOS is putatively considered parasympathetic
in origin (Edvinsson et al., 2001). Although the vasodilatory eﬀect of
NO on cerebral blood vessels has been experimentally proven (Olesen
et al., 1995), its role in migraine pathogenesis remains debated.
VIP is a neuropeptide known to cause a long lasting, diﬀuse
vasodilatation when systemically administered to the body (Said and
Mutt, 1972). Particularly, VIP induces relaxation of the cerebral vessel
musculature through an endothelium-independent mechanism
(Edvinsson et al., 1981). VIP-containing nerve ﬁbers are present around
blood vessels of the brain surface (Edvinsson and Kruse, 2002). This
neuropeptide sometimes co-localizes with AChE in perivascular nerve
ﬁbers of parasympathetic origin (Gulbenkian et al., 1991). Plasma VIP
levels are elevated during migraine headaches in patients who have
previously showed parasympathetic type symptoms (Goadsby et al.,
1990), and cat SSS stimulation strongly enhanced the quantity of VIP
circulating in cranial blood vessels (Zagami et al., 1990).
To our knowledge, CGRP and VIP co-localization in nerve structures
of the superﬁcial brain vessels has never been described. The presence
of CGRP has been detected immunohistochemically in nerve cell bodies
of the sphenopalatine ganglion (Silverman and Kruger, 1989) which
contains, as described above, also a good amount of VIP- positive
pirenophora (Uddman et al., 1999). On the other hand, the presence of
VIP-containing nerve cell bodies has never been described in the
trigeminal ganglion (Jansen-Olesen et al., 2014). On this basis, a
hypothetical source of CGRP/VIP-containing nerve ﬁbers could be a
nerve cell body localized in the sphenopalatine ganglion, which is
capable of producing both substances. However, further studies are
needed to test this hypothesis and establish the precise role of the
CGRP/VIP-containing ﬁbers here described.
4.3. TH/NPY-containing nerve ﬁbers
Keller et al. (1989) described close, but separate, networks of
dopamine β hydroxylase (DBH)- and NPY-immunoreactive nerve ﬁbers
around the walls of the rat SSS using whole mount preparations of the
supratentorial dura mater. In both cases, the immunoreactive ﬁbers
most likely originated by sympathetic cell bodies contained in the
superior cervical ganglion of each side because their ablation almost
completely removed the immunopositivities around the sinus. The
common sympathetic origin of the DBH- and NPY-containing nerve
ﬁbers and their similarity of distribution around the sinus led to
hypothesize that the two nerve networks were eﬀectively the same
(Keller et al., 1989). It was, in fact, already known that NPY-containing
nerve ﬁbers are diﬀusely distributed around the walls of cerebral
arteries (Edvinsson et al., 1983) and that DBH and NPY co-localize in
perivascular nerve ﬁbers at the surface of the brain (Edvinsson et al.,
1987). Later, also the inferior cervical ganglia of both sides and the
stellate ganglion were recognized as sources of the sympathetic nerve
supply to superﬁcial blood vessels of the brain (Edvinsson et al., 2012).
Our results concretely demonstrate that dense nerve networks contain-
ing the neuropeptides TH and NPY encircle the SSS walls and that the
two molecules often co-localize in the same ﬁbers.
Superior cervical ganglion-derived sympathetic nerve ﬁbers inner-
vating the cerebral blood vessels are vasomotor in function (Edvinsson
and Kruse, 2002) and the two mediators of this eﬀect, noradrenaline
(NA) and NPY, act synergistically on the vascular musculature (Ekblad
et al., 1984). However, the actions of these two compounds appear to
be diﬀerent, because the former is prominent under normal body
conditions, while the latter is more active during elevated sympathetic
activity (Lundberg et al., 1985). The vasomotor action of NPY on the
extracerebral vasculature seems to be exerted at level of pial arterioles,
which contain the Y1 receptor of the neuropeptide in large amounts just
before entering the brain. On the contrary, wider superﬁcial vessels,
although enveloped by a network of sympathetic ﬁbers, are devoid of
the Y1 receptor or show its presence at a lesser extent. Thus, these
major vessels can only internalize the neuropeptide whose target is
located elsewhere. More recently, an alternative source of NPY-contain-
ing nerve terminals surrounding the pial arterioles was found inside the
brain and is putatively represented by local interneurons producing the
peptide. Such control of the brain on regulation of its own vasculature is
suggestive (Hökfelt et al., 1998).
Currently, the purpose and function of TH/NPY-containing nerve
ﬁbers in the SSS wall is not known also because the presence of a
vasomotor innervation in the walls of a vessel-like structure almost
completely devoid of a muscle layer seems to be ineﬀective. However,
as reported above, actin has been detected around the openings of
bridging veins in the sinus, forming a muscle sphincter in which Ruﬃni-
like structures, supposed to be stretch receptors, have been described
Fig. 5. Western blotting analysis. Protein expression in samples from the SSS of two
human subjects (S1 and S2). The blots of the two lanes (S1 and S2) report the presence of
all neuropeptides studied in the SSS walls. The peptides are reported on the left of the
ﬁgure and the sizes on the right.
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(Andres et al., 1987; Vignes et al., 2007). In this study the presence of
SP-containing nerve ﬁbers has been often observed around the terminal
portion of bridging veins in the sinus and a possible CGRP/SP and TH/
NPY innervation of this portion could result in an antagonistic regula-
tion of blood inﬂux in the SSS. If extended to the openings of the major
bridging veins in the cerebral sinusal complex, such a study could
disclose the regulatory mechanism of blood eﬄux from the brain and,
consequently, of the cerebral blood homeostasis.
In conclusion, this work describes the existence of ramiﬁed net-
works of nerve ﬁbers within the walls of the SSS in the human brain.
Several neurotransmitters have been identiﬁed in such structures and
some of them were found to be co-localized in the same ﬁbers. Although
the neurotransmitter combinations recognized can be functionally
ascribed to diﬀerent components of the nervous system, further studies
are needed to clarify their function in SSS. Such acquisition could
translate in a better comprehension of the role played by the sinus in
regulation of the brain-blood homeostasis and in determinism of the
migraine and other primary headache pathogenesis.
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